BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 33146841)

  • 1. Diagnostic performance of MRI for HCC according to contrast agent type: a systematic review and meta-analysis.
    Kim DW; Choi SH; Kim SY; Byun JH; Lee SS; Park SH; Kim KW
    Hepatol Int; 2020 Dec; 14(6):1009-1022. PubMed ID: 33146841
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Diagnostic performance of MRI for residual or recurrent hepatocellular carcinoma after locoregional treatment according to contrast agent type: a systematic review and meta‑analysis.
    Zhou S; Wang S; Xiang J; Han Z; Wang W; Zhang S; Opara NC; Ju S; Cui Y; Wang YC
    Abdom Radiol (NY); 2024 Feb; 49(2):471-483. PubMed ID: 38200213
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Magnetic Resonance Imaging With Extracellular Contrast Detects Hepatocellular Carcinoma With Greater Accuracy Than With Gadoxetic Acid or Computed Tomography.
    Min JH; Kim JM; Kim YK; Cha DI; Kang TW; Kim H; Choi GS; Choi SY; Ahn S
    Clin Gastroenterol Hepatol; 2020 Aug; 18(9):2091-2100.e7. PubMed ID: 31843599
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of extracellular and hepatobiliary MR contrast agents for the diagnosis of small HCCs.
    Paisant A; Vilgrain V; Riou J; Oberti F; Sutter O; Laurent V; Rodes A; Guiu B; Cassinotto C; Trillaud H; Bricault I; Michalak S; Bruno O; Ronot M; Aubé C
    J Hepatol; 2020 May; 72(5):937-945. PubMed ID: 31870951
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Diagnosis of recurrent HCC: intraindividual comparison of gadoxetic acid MRI and extracellular contrast-enhanced MRI.
    Yim JH; Kim YK; Min JH; Lee J; Kang TW; Lee SJ
    Abdom Radiol (NY); 2019 Jul; 44(7):2366-2376. PubMed ID: 30847566
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Extracellular contrast-enhanced MRI with diffusion-weighted imaging for HCC diagnosis: prospective comparison with gadoxetic acid using LI-RADS.
    Cha DI; Choi GS; Kim YK; Kim JM; Kang TW; Song KD; Ahn SH
    Eur Radiol; 2020 Jul; 30(7):3723-3734. PubMed ID: 32128620
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intraindividual Comparison of Hepatocellular Carcinoma Washout between MRIs with Hepatobiliary and Extracellular Contrast Agents.
    Kim YY; Kim YK; Min JH; Cha DI; Kim JM; Choi GS; Ahn S
    Korean J Radiol; 2021 May; 22(5):725-734. PubMed ID: 33660458
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prospective Intraindividual Comparison of Magnetic Resonance Imaging With Gadoxetic Acid and Extracellular Contrast for Diagnosis of Hepatocellular Carcinomas Using the Liver Imaging Reporting and Data System.
    Min JH; Kim JM; Kim YK; Kang TW; Lee SJ; Choi GS; Choi SY; Ahn S
    Hepatology; 2018 Dec; 68(6):2254-2266. PubMed ID: 30070365
    [TBL] [Abstract][Full Text] [Related]  

  • 9. EASL versus LI-RADS: Intra-individual comparison of MRI with extracellular contrast and gadoxetic acid for diagnosis of small HCC.
    Min JH; Kim JM; Kim YK; Kim H; Cha DI; Kang TW; Choi GS; Choi SY; Ahn S
    Liver Int; 2021 Dec; 41(12):2986-2996. PubMed ID: 34242468
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A modified LI-RADS: targetoid tumors with enhancing capsule can be diagnosed as HCC instead of LR-M lesions.
    Min JH; Kim JM; Kim YK; Kim H; Choi GS; Kang TW; Cha D; Hwang JA; Ko SE; Ahn S
    Eur Radiol; 2022 Feb; 32(2):912-922. PubMed ID: 34345947
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Retrospective comparison of EASL 2018 and LI-RADS 2018 for the noninvasive diagnosis of hepatocellular carcinoma using magnetic resonance imaging.
    Lee S; Kim MJ; Kim SS; Shin H; Kim DY; Choi JY; Park MS; Mitchell DG
    Hepatol Int; 2020 Jan; 14(1):70-79. PubMed ID: 31802388
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Diagnostic performance of MRI using extracellular contrast agents versus gadoxetic acid for hepatocellular carcinoma: A systematic review and meta-analysis.
    Feng Z; Zhao H; Guan S; Wang W; Rong P
    Liver Int; 2021 May; 41(5):1117-1128. PubMed ID: 33647177
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of LI-RADS 2018 and KLCA-NCC 2018 for noninvasive diagnosis of hepatocellular carcinoma using magnetic resonance imaging.
    Lee S; Kim SS; Chang DR; Kim H; Kim MJ
    Clin Mol Hepatol; 2020 Jul; 26(3):340-351. PubMed ID: 32492765
    [TBL] [Abstract][Full Text] [Related]  

  • 14. LI-RADS Major Features on MRI for Diagnosing Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis.
    Shin J; Lee S; Yoon JK; Chung YE; Choi JY; Park MS
    J Magn Reson Imaging; 2021 Aug; 54(2):518-525. PubMed ID: 33638582
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Enhancing capsule in hepatocellular carcinoma: intra-individual comparison between CT and MRI with extracellular contrast agent.
    Cannella R; Ronot M; Sartoris R; Cauchy F; Hobeika C; Beaufrere A; Trapani L; Paradis V; Bouattour M; Bonvalet F; Vilgrain V; Dioguardi Burgio M
    Diagn Interv Imaging; 2021 Dec; 102(12):735-742. PubMed ID: 34284951
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of LI-RADS Version 2018 Treatment Response Algorithm for Hepatocellular Carcinoma in Liver Transplant Candidates: Intraindividual Comparison between CT and Hepatobiliary Agent-enhanced MRI.
    Bae JS; Lee JM; Yoon JH; Kang HJ; Jeon SK; Joo I; Lee KB; Kim H
    Radiology; 2021 May; 299(2):336-345. PubMed ID: 33650901
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Diagnostic performance of magnetic resonance imaging and contrast-enhanced ultrasound in differentiating intrahepatic cholangiocarcinoma from hepatocellular carcinoma: a meta-analysis.
    Wu Y; Xia C; Chen J; Qin Q; Ye Z; Song B
    Abdom Radiol (NY); 2024 Jan; 49(1):34-48. PubMed ID: 37823913
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Extracellular contrast agent-enhanced MRI: 15-min delayed phase may improve the diagnostic performance for hepatocellular carcinoma in patients with chronic liver disease.
    Lee SE; An C; Hwang SH; Choi JY; Han K; Kim MJ
    Eur Radiol; 2018 Apr; 28(4):1551-1559. PubMed ID: 29134355
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Assessing locoregional treatment response to Hepatocellular Carcinoma: comparison of hepatobiliary contrast agents to extracellular contrast agents.
    Aslam A; Kamath A; Spieler B; Maschiocchi M; Sabottke CF; Chernyak V; Lewis SC
    Abdom Radiol (NY); 2021 Aug; 46(8):3565-3578. PubMed ID: 33856509
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Imaging Features of Hepatocellular Carcinoma: Quantitative and Qualitative Comparison Between MRI-Enhanced With Gd-EOB-DTPA and Gd-DTPA.
    Son J; Hwang SH; Park S; Han K; Chung YE; Choi JY; Kim MJ; Park MS
    Invest Radiol; 2019 Aug; 54(8):494-499. PubMed ID: 31094878
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.